{"id":62557,"date":"2026-04-07T21:40:36","date_gmt":"2026-04-07T13:40:36","guid":{"rendered":"https:\/\/flcube.com\/?p=62557"},"modified":"2026-04-07T21:40:38","modified_gmt":"2026-04-07T13:40:38","slug":"amgens-subcutaneous-tepezza-via-on-body-injector-meets-phase-iii-endpoint-in-thyroid-eye-disease-with-77-proptosis-response","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62557","title":{"rendered":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response"},"content":{"rendered":"\n<p><strong>Amgen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AMGN:NASDAQ\">NASDAQ: AMGN<\/a>) announced <strong>positive top-line results<\/strong> from a <strong>Phase III clinical trial<\/strong> evaluating <strong>Tepezza\u00ae (teprotumumab)<\/strong> administered <strong>subcutaneously via an on-body injector (OBI)<\/strong> in patients with <strong>moderately-to-severely active thyroid eye disease (TED)<\/strong>. The subcutaneous formulation demonstrated <strong>non-inferior efficacy<\/strong> to the established intravenous (IV) regimen, achieving a <strong>statistically significant and clinically meaningful proptosis response rate of 77%<\/strong> (<em>P<\/em> &lt; 0.0001) at Week 24 versus placebo.<\/p>\n\n\n\n<p>The study also met its key secondary endpoint, with a <strong>mean proptosis reduction of \u20133.17 mm<\/strong> (<em>P<\/em> &lt; 0.0001), reinforcing Tepezza\u2019s role as the <strong>first and only approved immunotherapy targeting the insulin-like growth factor-1 receptor (IGF-1R)<\/strong> in TED\u2014a rare, vision-threatening autoimmune disorder affecting orbital tissues.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-highlights\">Clinical Trial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Tepezza OBI Result<\/th><th><em>P<\/em>-Value<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: Proptosis Response Rate<\/strong> (\u22652 mm reduction in both eyes)<\/td><td><strong>77%<\/strong><\/td><td>&lt; 0.0001<\/td><td>Clinically meaningful improvement in eye bulging<\/td><\/tr><tr><td><strong>Key Secondary: Mean Proptosis Reduction<\/strong><\/td><td><strong>\u20133.17 mm<\/strong><\/td><td>&lt; 0.0001<\/td><td>Exceeds minimal clinically important difference (MCID \u2248 \u20132 mm)<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with IV formulation; no new safety signals<\/td><td>\u2014<\/td><td>Most common AEs: transient hyperglycemia, muscle spasm, alopecia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-amp-therapeutic-context\">Disease &amp; Therapeutic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Thyroid Eye Disease (TED)<\/strong>: A progressive autoimmune condition driven by <strong>autoantibodies activating IGF-1R<\/strong> on orbital fibroblasts, leading to inflammation, fat expansion, and proptosis. Occurs primarily in <strong>Graves\u2019 disease patients<\/strong> but is a <strong>distinct pathological entity<\/strong>.<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Prior to Tepezza, treatment options were limited to corticosteroids, orbital radiation, or invasive surgery\u2014none targeting the underlying molecular mechanism.<\/li>\n\n\n\n<li><strong>Tepezza Milestones<\/strong>:<\/li>\n\n\n\n<li><strong>US FDA Approval<\/strong>: January 2020 (IV formulation)<\/li>\n\n\n\n<li><strong>EU Marketing Authorization<\/strong>: June 2025<\/li>\n\n\n\n<li><strong>UK MHRA Approval<\/strong>: July 2025<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: The <strong>OBI delivery system<\/strong> enables <strong>at-home administration<\/strong>, reducing clinic visits and improving patient convenience while maintaining therapeutic equivalence.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-amp-strategic-outlook\">Commercial &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Position<\/strong>: Tepezza generated <strong>$2.1 billion in global sales in 2025<\/strong>, with TED prevalence estimated at <strong>16\u201319 cases per 100,000 adults<\/strong> in the US and EU.<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Remains the <strong>only IGF-1R\u2013targeted therapy<\/strong> approved for TED; no biosimilars or direct competitors expected before 2030.<\/li>\n\n\n\n<li><strong>Next Steps<\/strong>: Amgen plans to submit <strong>regulatory filings for the OBI formulation<\/strong> in the US, EU, and UK in H2 2026, supported by this pivotal data.<\/li>\n\n\n\n<li><strong>Patient Impact<\/strong>: Subcutaneous delivery could expand access in rural or underserved regions and improve long-term adherence.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory submissions, market potential, and clinical development. Actual outcomes may differ due to regulatory decisions, competitive developments, and clinical adoption trends.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62559,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,17,912,44,24],"class_list":["post-62557","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-clinical-trial-results","tag-nasdaq-amgn","tag-ophthalmology","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating Tepezza\u00ae (teprotumumab) administered subcutaneously via an on-body injector (OBI) in patients with moderately-to-severely active thyroid eye disease (TED). The subcutaneous formulation demonstrated non-inferior efficacy to the established intravenous (IV) regimen, achieving a statistically significant and clinically meaningful proptosis response rate of 77% (P &lt; 0.0001) at Week 24 versus placebo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62557\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response\" \/>\n<meta property=\"og:description\" content=\"Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating Tepezza\u00ae (teprotumumab) administered subcutaneously via an on-body injector (OBI) in patients with moderately-to-severely active thyroid eye disease (TED). The subcutaneous formulation demonstrated non-inferior efficacy to the established intravenous (IV) regimen, achieving a statistically significant and clinically meaningful proptosis response rate of 77% (P &lt; 0.0001) at Week 24 versus placebo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62557\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:40:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T13:40:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response\",\"datePublished\":\"2026-04-07T13:40:36+00:00\",\"dateModified\":\"2026-04-07T13:40:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0703.webp\",\"keywords\":[\"Amgen\",\"Clinical trial results\",\"NASDAQ: AMGN\",\"Ophthalmology\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62557#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62557\",\"name\":\"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0703.webp\",\"datePublished\":\"2026-04-07T13:40:36+00:00\",\"dateModified\":\"2026-04-07T13:40:38+00:00\",\"description\":\"Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating Tepezza\u00ae (teprotumumab) administered subcutaneously via an on-body injector (OBI) in patients with moderately-to-severely active thyroid eye disease (TED). The subcutaneous formulation demonstrated non-inferior efficacy to the established intravenous (IV) regimen, achieving a statistically significant and clinically meaningful proptosis response rate of 77% (P &lt; 0.0001) at Week 24 versus placebo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62557\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62557#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response - Insight, China&#039;s Pharmaceutical Industry","description":"Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating Tepezza\u00ae (teprotumumab) administered subcutaneously via an on-body injector (OBI) in patients with moderately-to-severely active thyroid eye disease (TED). The subcutaneous formulation demonstrated non-inferior efficacy to the established intravenous (IV) regimen, achieving a statistically significant and clinically meaningful proptosis response rate of 77% (P &lt; 0.0001) at Week 24 versus placebo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62557","og_locale":"en_US","og_type":"article","og_title":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response","og_description":"Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating Tepezza\u00ae (teprotumumab) administered subcutaneously via an on-body injector (OBI) in patients with moderately-to-severely active thyroid eye disease (TED). The subcutaneous formulation demonstrated non-inferior efficacy to the established intravenous (IV) regimen, achieving a statistically significant and clinically meaningful proptosis response rate of 77% (P &lt; 0.0001) at Week 24 versus placebo.","og_url":"https:\/\/flcube.com\/?p=62557","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-07T13:40:36+00:00","article_modified_time":"2026-04-07T13:40:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62557#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62557"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response","datePublished":"2026-04-07T13:40:36+00:00","dateModified":"2026-04-07T13:40:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62557"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62557#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp","keywords":["Amgen","Clinical trial results","NASDAQ: AMGN","Ophthalmology","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62557#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62557","url":"https:\/\/flcube.com\/?p=62557","name":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62557#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62557#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp","datePublished":"2026-04-07T13:40:36+00:00","dateModified":"2026-04-07T13:40:38+00:00","description":"Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating Tepezza\u00ae (teprotumumab) administered subcutaneously via an on-body injector (OBI) in patients with moderately-to-severely active thyroid eye disease (TED). The subcutaneous formulation demonstrated non-inferior efficacy to the established intravenous (IV) regimen, achieving a statistically significant and clinically meaningful proptosis response rate of 77% (P &lt; 0.0001) at Week 24 versus placebo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62557#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62557"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62557#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp","width":1080,"height":608,"caption":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62557#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amgen\u2019s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62557"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62557\/revisions"}],"predecessor-version":[{"id":62560,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62557\/revisions\/62560"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62559"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}